Posted On: 07/15/2014 8:10:14 PM
Post# of 6

VODG Financials 07/15/2014 19:10:17
Vitro Diagnostics, Inc.
Period Ending Oct 31, 2013 Oct 31, 2012 Oct 31, 2011 Oct 31, 2010
Total Revenue 35 28 23 16
Cost of Revenue 15 13 9 7
Gross Profit 20 15 14 8
Operating Expenses
Research and Development 120 126 138 178
Sales, General and Admin. 51 68 78 92
Non-Recurring Items - - - -
Other - - - -
Operating Income (151) (179) (202) (261)
Income From Continuing Operations
Add'l Income/Expense Items - - 229 46
Earnings Before Interest and Tax (151) (179) 27 (216)
Interest Expense 60 49 41 42
Earnings Before Tax (211) (228) (14) (257)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (211) (228) 176 (257)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (211) (228) (14) (257)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (211) (228) (14) (257)
Vitro Diagnostics, Inc.
Period Ending Oct 31, 2013 Oct 31, 2012 Oct 31, 2011 Oct 31, 2010
Total Revenue 35 28 23 16
Cost of Revenue 15 13 9 7
Gross Profit 20 15 14 8
Operating Expenses
Research and Development 120 126 138 178
Sales, General and Admin. 51 68 78 92
Non-Recurring Items - - - -
Other - - - -
Operating Income (151) (179) (202) (261)
Income From Continuing Operations
Add'l Income/Expense Items - - 229 46
Earnings Before Interest and Tax (151) (179) 27 (216)
Interest Expense 60 49 41 42
Earnings Before Tax (211) (228) (14) (257)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (211) (228) 176 (257)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (211) (228) (14) (257)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (211) (228) (14) (257)

